Exciting insights into #BladderCancer development: This study explores the link between APOBEC-type mutations, viral infections like BK polyomavirus (BKPyV), and environmental factors like smoking. #ReadNow on UroToday > bit.ly/3IV4cge Dr. Bishoy M. Faltas

Erdafitinib or chemotherapy in advanced or metastatic #UrothelialCarcinoma . Arlene Siefker-Radtke MD Anderson Cancer Center joins Sam S. Chang MD, MBA Vanderbilt Urology to discuss the transformative impact of erdafitinib in treating advanced and metastatic urothelial cancer > bit.ly/3v1rqhK

The role of gene therapy in enhancing #BladderCancer patient outcomes. Mark Tyson Mayo Clinic joins Neal Shore, MD, FACS CURC to discuss advances in #NMIBC treatments, particularly for BCG-unresponsive patients. #WatchNow > bit.ly/42Sdram Ferring Pharmaceuticals

Urethroplasty outcomes for pars fixa urethral strictures following gender-affirming phalloplasty and metoidioplasty: a retrospective study. #BeyondTheAbstract on UroToday > bit.ly/3wVyX24 Richard Wassersug Urology Gold Journal

The role of PSMA PET in #CRPC patients. Presentation by Wolfgang Fendler, MD VomLaborInDiePraxis emphasizing the transformative role of PSMA-PET imaging in managing CRPC, showcasing its ability to reveal a more extensive disease burden and detect distant metastases > bit.ly/490mrLY

Cretostimogene grenadenorepvec in BCG-unresponsive #NMIBC : a discussion on the #BOND -003 and #CORE1 trials. Trinity J. Bivalacqua Penn joins Sam S. Chang MD, MBA Vanderbilt Urology to discuss treatments in NMIBC, CG0070 & its efficacy in managing BCG-unresponsive CIS > bit.ly/4a6uS9m CG Oncology, Inc.

PSMA PET selection of patients for PSMA radiopharmaceutical therapy. Presentation by Jeremie Calais @ucla discussing the crucial role of PSMA PET at the 2024 PSMA conference - UCSF/UCLA/PCF/Urotoday. #WatchNow on UroToday > bit.ly/43uVS0x UC San Francisco Prostate Cancer Foundation

I’m thrilled to be a co-chair for the AACR Special Conference in #Cancer Research: “ #BladderCancer : Transforming the Field” on 5/17-20 in Charlotte. Global leaders will cover core biological principles, disease models, clinical aspects and use of #AI . aacr.org/meeting/aacr-s…

#BladderCancer : En bloc resection technique shows promise. David D'Andrea, MD MedUni Wien joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss the #eBLOC trial, focusing on en-bloc versus conventional resection of bladder tumors. #WatchNow on UroToday > bit.ly/3V2hdfy

Navigating #NMIBC risk stratification and treatment. Neal Shore CURC joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss the crucial role of the Amer. Urol. Assn. guidelines, developed with significant contributions from Dr. Kamat and other leaders in the field > bit.ly/4ab7He6

A phase I clinical trial evaluating the safety and dosing of relugolix with novel hormonal therapy for the treatment of advanced #ProstateCancer . #BeyondTheAbstract with Jose De La Cerda, MD Urology San Antonio on UroToday > bit.ly/3TlYxVm Targeted Oncology

Trials evaluating the impact of PSMA PET on management and outcomes. Presentation from Amar Kishan UCLA discussing PSMA PET imaging and its role in refining intermediate clinical endpoints like metastasis-free survival > bit.ly/3PmZw6N PSMA conference - UCSF/UCLA/PCF/Urotoday

The impact of screening practices for Black men. Leanne Woods-Burnham Morehouse School of Medicine joins SamWashUro UCSFUrology to discuss this important issue, emphasizing the decline in localized #ProstateCancer detection following 2012 guideline changes > bit.ly/3vbkmim

Breaking Paradigms: #Cretostimogene monotherapy #BOND -003 demonstrates significant durability & tolerability with no major AEs. FDA grants Fast Track & Breakthrough Therapy designation. Mark Tyson discusses on UroToday > bit.ly/4aZcGQ8 #BladderCancer CG Oncology, Inc.

Coordinating complex care in high-volume #mHSPC through multidisciplinary communication. Jonathan Henderson, MD Arkansas Urology & Sunil Kakadia, MD, MPH, FACP join Alicia Morgans, MD, MPH Dana-Farber in this discussion on managing high-volume mHSPC > bit.ly/4a3TlfY

Optimizing treatment in metastatic hormone-sensitive #ProstateCancer : a case study analysis. Alicia Morgans, MD, MPH Dana-Farber joins Elena Castro in discussing the State of the Art of prostate cancer in 2024. #WatchNow on UroToday > bit.ly/3TfYETO Bayer | Pharmaceuticals

Exciting insights from the 2024 UC San Francisco UCLA PSMA conference - UCSF/UCLA/PCF/Urotoday! Michael Morris Memorial Sloan Kettering Cancer Center emphasized the pivotal role of PSMA PET in #ProstateCancer mgmt, navigating its regulatory journey and challenges in interpretation. #WatchNow > bit.ly/3wduQhk Prostate Cancer Foundation

The #COMBAT trial yields promising results for bipolar androgen therapy + nivolumab in #mCRPC . Mark C. Markowski Johns Hopkins Kimmel Cancer Center & Emmanuel Antonarakis University of Minnesota join Alicia Morgans, MD, MPH Dana-Farber discussing research on high-dose testosterone therapy for #mCRPC > bit.ly/3PhLeEn

Advancing #ProstateCancer diagnosis: An international validation study evaluates the accuracy of an AI tool, HALO Prostate AI, in detecting cancer and grading Gleason scores. A promising step toward more efficient and precise diagnoses. #ReadNow > bit.ly/3IZR7T7

Exciting insights from Philipose Mulugeta! Learn how PSMA PET/CT revolutionizes salvage radiation planning in biochemical recurrence post-prostatectomy. Discover its pivotal role in detecting metastatic disease and guiding personalized treatment strategies SNMMI